| Bid | 0.78 |
| Market Cap | 22.13M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.1 |
| PE Ratio (ttm) | -0.38 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.99 |
| Volume | 30,148 |
| Avg. Volume (20D) | 149,447 |
| Open | 0.78 |
| Previous Close | 0.78 |
| Day's Range | 0.78 - 0.81 |
| 52-Week Range | 0.76 - 2.57 |
| Beta | undefined |
About NXTC
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune sup...
Analyst Forecast
According to 2 analyst ratings, the average rating for NXTC stock is "Buy." The 12-month stock price forecast is $4, which is an increase of 406.33% from the latest price.
9 months ago · investorplace.com
Wall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy RichThe bullish sentiment in the market is leading some investors to look at risk-on assets. Bitcoin may be an option, but for investors who prefer to stay in stocks, it may be time to look for some of th...
